FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013463833> ?p ?o ?g. }

• W3013463833 endingPage "119256" @default.
• W3013463833 startingPage "119256" @default.
• W3013463833 abstract "Flavonoids inhibit skin inflammation. Previous study suggests that the flavonoids with flavanone backbone were beneficial to penetrate into the skin. We aimed to investigate the possibility of psoriasis treatment by topically applied flavanone and its derivatives including naringenin, hesperetin, 6-hydroxyflavanone, flavanone, and 6-bromoflavone. The skin absorption of the compounds was determined by Franz cells. Molecular modeling was used to compute the physicochemical and molecular parameters of the penetrants in order to elucidate the correlation between structure and permeation. Among the compounds tested, flavanone showed the greatest skin absorption. The in vitro skin absorption predicted efficient skin targeting of 6-bromoflavone with minimal risk of circulation absorption. The permeation of naringenin was remarkably enhanced 13-fold in the barrier-defective skin mimicking inflamed skin. The penetrants with fewer hydrogen bond number, total polarity surface, and molecular volume were advantageous for facile skin absorption. In the cell-based study, IL-1β inhibition in imiquimod (IMQ)-stimulated keratinocytes was increased following the increase in compound lipophilicity. Naringenin, a flavanone analog with three hydroxyl moieties, could suppress IL-6 overexpression to baseline control. We assessed the anti-inflammatory potency of the chemicals in comparison with tacrolimus as reference in a psoriasis-like mouse model. Flavanone was found to mitigate scaling and epidermal hyperplasia at a higher level than naringenin. Flavanone lessened IL-6 overexpression by 80% in the psoriasiform plaque. The skin barrier function recorded by transepidermal water loss (TEWL) was recovered by naringenin but not flavanone. The experimental data indicate that naringenin and flavanone are potential candidates for anti-psoriatic therapy." @default.
• W3013463833 created "2020-04-03" @default.
• W3013463833 creator A5025830476 @default.
• W3013463833 creator A5025906985 @default.
• W3013463833 creator A5026838204 @default.
• W3013463833 creator A5038455844 @default.
• W3013463833 creator A5045372270 @default.
• W3013463833 creator A5048989451 @default.
• W3013463833 creator A5062927992 @default.
• W3013463833 date "2020-05-01" @default.
• W3013463833 modified "2023-10-15" @default.
• W3013463833 title "Development of flavanone and its derivatives as topical agents against psoriasis: The prediction of therapeutic efficiency through skin permeation evaluation and cell-based assay" @default.
• W3013463833 cites W1805348119 @default.
• W3013463833 cites W1964167302 @default.
• W3013463833 cites W1972544618 @default.
• W3013463833 cites W1979103494 @default.
• W3013463833 cites W1993461009 @default.
• W3013463833 cites W1995219736 @default.
• W3013463833 cites W2007146099 @default.
• W3013463833 cites W2012299963 @default.
• W3013463833 cites W2021005040 @default.
• W3013463833 cites W2026430306 @default.
• W3013463833 cites W2026709799 @default.
• W3013463833 cites W2033495141 @default.
• W3013463833 cites W2037005592 @default.
• W3013463833 cites W2037827983 @default.
• W3013463833 cites W2040115324 @default.
• W3013463833 cites W2052655407 @default.
• W3013463833 cites W2053064763 @default.
• W3013463833 cites W2072344392 @default.
• W3013463833 cites W2084856901 @default.
• W3013463833 cites W2089257120 @default.
• W3013463833 cites W2100023645 @default.
• W3013463833 cites W2110519221 @default.
• W3013463833 cites W2127377425 @default.
• W3013463833 cites W2162845988 @default.
• W3013463833 cites W2164408224 @default.
• W3013463833 cites W2182617457 @default.
• W3013463833 cites W2280739725 @default.
• W3013463833 cites W2295160524 @default.
• W3013463833 cites W2337627026 @default.
• W3013463833 cites W2345988321 @default.
• W3013463833 cites W2366525140 @default.
• W3013463833 cites W2413921173 @default.
• W3013463833 cites W2414766522 @default.
• W3013463833 cites W2472739606 @default.
• W3013463833 cites W2498527833 @default.
• W3013463833 cites W2513846754 @default.
• W3013463833 cites W2529977718 @default.
• W3013463833 cites W2539085880 @default.
• W3013463833 cites W2560615235 @default.
• W3013463833 cites W2565883611 @default.
• W3013463833 cites W2592200658 @default.
• W3013463833 cites W2598403906 @default.
• W3013463833 cites W2605664204 @default.
• W3013463833 cites W2719284731 @default.
• W3013463833 cites W2771646433 @default.
• W3013463833 cites W2790423016 @default.
• W3013463833 cites W2809235299 @default.
• W3013463833 cites W2811171873 @default.
• W3013463833 cites W2888718707 @default.
• W3013463833 cites W2924895007 @default.
• W3013463833 cites W2935101021 @default.
• W3013463833 cites W2966093265 @default.
• W3013463833 cites W2971933937 @default.
• W3013463833 cites W780388304 @default.
• W3013463833 doi "https://doi.org/10.1016/j.ijpharm.2020.119256" @default.
• W3013463833 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32220586" @default.
• W3013463833 hasPublicationYear "2020" @default.
• W3013463833 type Work @default.
• W3013463833 sameAs 3013463833 @default.
• W3013463833 citedByCount "21" @default.
• W3013463833 countsByYear W30134638332020 @default.
• W3013463833 countsByYear W30134638332021 @default.
• W3013463833 countsByYear W30134638332022 @default.
• W3013463833 countsByYear W30134638332023 @default.
• W3013463833 crossrefType "journal-article" @default.
• W3013463833 hasAuthorship W3013463833A5025830476 @default.
• W3013463833 hasAuthorship W3013463833A5025906985 @default.
• W3013463833 hasAuthorship W3013463833A5026838204 @default.
• W3013463833 hasAuthorship W3013463833A5038455844 @default.
• W3013463833 hasAuthorship W3013463833A5045372270 @default.
• W3013463833 hasAuthorship W3013463833A5048989451 @default.
• W3013463833 hasAuthorship W3013463833A5062927992 @default.
• W3013463833 hasConcept C125287762 @default.
• W3013463833 hasConcept C142724271 @default.
• W3013463833 hasConcept C159985019 @default.
• W3013463833 hasConcept C16005928 @default.
• W3013463833 hasConcept C185592680 @default.
• W3013463833 hasConcept C192562407 @default.
• W3013463833 hasConcept C2776848411 @default.
• W3013463833 hasConcept C2777481717 @default.
• W3013463833 hasConcept C2778004101 @default.
• W3013463833 hasConcept C2778370115 @default.
• W3013463833 hasConcept C2779054382 @default.
• W3013463833 hasConcept C2780564577 @default.
• W3013463833 hasConcept C41625074 @default.
• W3013463833 hasConcept C50670333 @default.

• next